We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Classification of Mature B-Cell Neoplasms Employing Standardized Flow Cytometry

By LabMedica International staff writers
Posted on 08 Dec 2021
The classification of lymphoid neoplasms integrates clinical, pathological, immunophenotypic, genetic, and molecular data in order to distinguish between mature B-cell lymphoma entities. More...
The precise classification of these entities (also known as B-cell chronic lymphoproliferative diseases, B-CLPD) has relevant therapeutic implications.

Immunophenotypic data combined with morphology, molecular, genetic, and clinical findings already contribute to the classification of mature B-cell neoplasms. Compared to other techniques, flow cytometry might be an advantageous method to assess the immunophenotype by virtue of its short turn-around time, its high dynamic range, its high sensitivity for rare cells, its potential for standardization and its world-wide availability.

An International team of scientists led by those at the Rostock University Medical School (Rostock, Germany) studied 662 samples from an identical number of patients comprising of 145 chronic lymphocytic leukemia (CLL), 58 hairy cell leukemia (HCL), 29 Burkitt lymphoma (BL), 104 diffuse large B-cell (DLBCL), 129 follicular (FL), 74 lymphoplasmacytic (LPL), 76 mantle cell (MCL), and 47 marginal zone (MZL) lymphoma cases. In addition, 501 consecutive samples with a suspicion of lymphoma infiltration from 501 patients were acquired at two centers between March 14, 2020 and September 30, 2021.

The scientists used the EuroFlow 5-tube-8-color B-cell chronic lymphoproliferative disease antibody panel (EuroFlow, Leiden, The Netherlands). Expression levels of all 26 markers from the panel were plotted by B-cell entity to construct a univariate, fully standardized diagnostic reference library. For multivariate data analysis they subsequently utilized Canonical Correlation Analysis of 176 training cases to project the multi-dimensional space of all 26 immunophenotypic parameters into 36 two-dimensional plots for each possible pair-wise differential diagnosis. Diagnostic boundaries were fitted according to the distribution of the immunophenotypes of a given differential diagnosis. The team developed a diagnostic algorithm based on these projections was developed and subsequently validated using 486 independent cases.

The investigators reported that the negative predictive values exceeding 92.1% were observed for all disease categories except for follicular lymphoma. Particularly high positive predictive values were returned in chronic lymphocytic leukemia (99.1%), hairy cell leukemia (97.2%), follicular lymphoma (97.2%) and mantle cell lymphoma (95.4%). Burkitt and CD10+ diffuse large B-cell lymphomas were difficult to distinguish by the algorithm. A similar ambiguity was observed between marginal zone, lymphoplasmacytic, and CD10- diffuse large B-cell lymphomas. The specificity of the approach exceeded 98% for all entities.

The authors concluded that in summary, algorithm guided expert-independent flow cytometric classification of mature B cell neoplasms can contribute to a reliable diagnosis in the majority of these lymphomas. The method will very likely reduce inter-center variation at this particular diagnostic step and will objectively inform on the relative contribution of flow cytometric data to the integrated overall diagnosis of lymphoma entities. The study was published on November 23, 2021 in the journal Blood Advances.

Related Links:
Rostock University Medical School
EuroFlow



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers

Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: The proposed immunoassay uses ALZpath’s pTau217 antibody to detect Alzheimer’s disease biology in blood, supporting the growing role of blood-based biomarkers in clinical care (Photo courtesy of Shutterstock)

Agreement Supports pTau217-Based Alzheimer’s Blood Test Development

As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.